New Releases from NCBI BookshelfToripalimab (Loqtorzi): Therapeutic area: Recurrent or metastatic nasopharyngeal carcinoma: Reimbursement Review [Internet].​Toripalimab (Loqtorzi): Therapeutic area: Recurrent or metastatic nasopharyngeal carcinoma: Reimbursement Review [Internet].

Nasopharyngeal carcinoma (NPC) is a rare malignancy of the nasopharynx with distinct features; it has strong geographic and ethnic variation due to its association with Epstein-Barr virus and other risk factors. While the 5-year overall survival (OS) rate in Canada is 70% for all stages, up to 30% of patients still experience recurrence — half of these within 2 years of initial treatment.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top